← Back to Clinical Trials
Recruiting NCT05835102

NCT05835102 Influence of Nutritional Indices on the Prognosis of Patients With SARS-CoV-2 Infection

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05835102
Status Recruiting
Phase
Sponsor Juan Kang
Condition COVID-19
Study Type OBSERVATIONAL
Enrollment 800 participants
Start Date 2023-05-01
Primary Completion 2025-12-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 800 participants in total. It began in 2023-05-01 with a primary completion date of 2025-12-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

With the decline of virulence after the mutation of the SARS-CoV-2 , based on the national life and health and national development needs, the domestic SARS-CoV-2 infection epidemic prevention policy has changed, and the number of people infected by the SARS-CoV-2 has increased. Nutritional status is an indicator of human health and plays an important role in fighting disease. Malnutrition has been found to correlate with prognosis in patients infected with the SARS-CoV-2 infection . Timely identification and assessment of the patient's nutritional status and early implementation of relevant nutritional intervention are conducive to the recovery of the patient's condition. In clinical practice, it is necessary to improve nutrition as an aspect of the comprehensive diagnosis and treatment of patients with SARS-CoV-2 infection, but there is still a lack of relevant nutritional indicators or models to simply and accurately assess the nutritional status of patients.The purpose of this study was to evaluate the effects of PNI, NRI, GNRI, albumin level, vitamin D, chest muscle area and density on the clinical characteristics and prognosis of patients with SARS-CoV-2 infection, to find the nutritional predictors of severe disease in patients with SARS-CoV-2 infection, and to establish a simpler and more accurate nutritional evaluation model. To provide evidence for targeted nutritional interventions in patients with SARS-CoV-2 infection.

Eligibility Criteria

Inclusion Criteria: Patients with a positive SARS-CoV-2 nucleic acid test or a positive SARS-CoV-2 antigen test. Exclusion Criteria: 1. People with end-stage malignant tumors; 2. Nutritional intake disorders, mainly dependent on enteral and parenteral nutrition supporters; 3. paralyzed; 4. Intravenous drug addicts.

Contact & Investigator

Central Contact

Juan Kang, M.D.

✉ 68368892@qq.com

📞 8613996112052

Principal Investigator

Juan Kang, M.D.

STUDY CHAIR

The Second Affiliated Hospital of Chongqing Medical University

Frequently Asked Questions

Who can join the NCT05835102 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying COVID-19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05835102 currently recruiting?

Yes, NCT05835102 is actively recruiting participants. Contact the research team at 68368892@qq.com for enrollment information.

Where is the NCT05835102 trial being conducted?

This trial is being conducted at Chongqing, China.

Who is sponsoring the NCT05835102 clinical trial?

NCT05835102 is sponsored by Juan Kang. The principal investigator is Juan Kang, M.D. at The Second Affiliated Hospital of Chongqing Medical University. The trial plans to enroll 800 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology